Bifidobacterium animalis subsp. lactis BLa36 for Constipation Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for slow transit constipation are ineffective in providing long-term relief and often cause adverse reactions, with limited microbial preparations available for constipation management.

Innovation Solution

The use of Bifidobacterium animalis subsp. lactis BLa36, cultured on MRS medium and combined with a protective agent and prebiotics, to create a probiotic preparation that enhances gastric acid resistance and intestinal transit rates, increasing fecal moisture content and beneficial bacteria abundance without adverse reactions.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conservative medical treatment is used for slow transit constipation, then symptoms can be temporarily relieved, but long-term therapeutic effect is poor and cannot solve the problem fundamentally

Engineering Contradiction:

Improvelong-term therapeutic effectVSAvoidduration of symptom relief

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The probiotic preparation contains Bifidobacterium animalis subsp. lactis BLa36 which can self-replicate and colonize the intestinal tract, continuously producing beneficial effects without requiring repeated medical interventions. The bacteria establish themselves in the gut microbiota and provide ongoing therapeutic action, transforming the treatment from temporary external relief to sustained self-maintaining therapy.

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The probiotic bacteria act as an intermediary between the administered treatment and the intestinal function. Instead of directly administering drugs that temporarily relieve symptoms, the live bacteria serve as living mediators that colonize the gut, interact with the intestinal environment, and continuously regulate bowel function through their metabolic activities and interaction with the host's microbiota.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If medications that increase fecal moisture content and gastrointestinal vitality are used, then constipation symptoms improve, but side effects occur

Engineering Contradiction:

Improveeffectiveness in relieving constipationVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Instead of using drugs that chemically alter gastrointestinal parameters and cause side effects, the invention changes the approach by introducing live bacteria that naturally modify the intestinal environment. The probiotic bacteria alter fecal moisture content, pH, and microbial composition through their metabolic activities, achieving therapeutic effects through biological parameter changes rather than pharmacological intervention.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The probiotic preparation is formulated as a composite containing Bifidobacterium animalis subsp. lactis BLa36 combined with protective agents and prebiotics. This composite structure protects the bacteria during gastric passage and enhances their colonization efficiency, while the prebiotics provide additional beneficial substrates, creating a synergistic formulation that improves effectiveness without adding pharmacological side effects.

Inventive Principle:

Principle #40Composite materials

3Adaptability or versatility

If microbial preparations are used for constipation treatment, then alternative therapy is provided, but effectiveness needs further improvement

Engineering Contradiction:

Improvealternative therapy optionVSAvoideffectiveness in relieving constipation

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The probiotic preparation is specifically designed with targeted functionality for slow transit constipation. The Bifidobacterium animalis subsp. lactis BLa36 strain was selected and optimized for its specific ability to improve intestinal motility and regulate bowel function. The formulation includes components specifically chosen to enhance colonization in the colon where they can directly affect transit time, providing localized therapeutic action tailored to the specific pathology rather than general gastrointestinal effects.

Inventive Principle:

Principle #3Local quality

Data Source

PatentUS20240287447A1Bifidobacterium animalis subsp. lactis bla36 for relieving constipation, method for culturing same, and use thereof

Publication Date: 2024.08.29 JIANGSU WECARE BIOTECHNOLOGY CO LTD

AI summary

The present invention provides a Bifidobacterium animalis subsp. lactis strain BLa36 for relieving constipation, a method for culturing same, and use thereof. The Bifidobacterium animalis subsp. lactis strain BLa36 for relieving constipation is designated as Bifidobacterium animalis subsp. lactis BLa36, which has been deposited at the China General Microbiological Culture Collection Center on Dec. 2, 2021, with an accession number of CGMCC No. 24029, and the address for the deposition is Yard No. 1(3), West Beichen Road, Chaoyang District, Beijing, China. The Bifidobacterium animalis subsp. lactis has good resistance to stomach acid and can relieve constipation.